Aravive Investor Presentation Deck

Market Research Suggests Batiraxcept Would Fill an Unmet Need and Be Adopted into the Current PROC Treatment Paradigm Improved Efficacy over SOC Favorable Safety Compared to Bey Doublets Favorable efficacy and a novel MOA were met with enthusiasm given ability to address unmet needs Physicians deemed the lack of additional toxicity to be impressive for a doublet regimen, particularly in comparison to bevacizumab in the U.S. "Platinum resistant patients are in need of new targeted treatment options."- Healthcare Provider "The all-comers data is helpful to know, but the bev-naïve data is quite transformative."- KOL "To see this level of safety with the improved efficacy is impressive- certainly would use this product." - KOL "Bevacizumab is only used as a palliative agent in my practice. I've had patients develop clots and bowel perforations from it, and the limited efficacy it may provide is not worth that risk." -Healthcare Provider Note: physicians' comments based on P1b data 20

View entire presentation